Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Space is Marked by Increasing Investment

The acute lymphocytic/lymphoblastic leukemia therapeutics market majorly consists of regimen therapies, namely, Hyper-CVAD, Linker, and CALGB 8811. In addition, Clolar, Arranon, and Oncaspar are the only available mono-therapy treatments in the market.

ERYTECH Pharma, Spectrum Pharmaceuticals (previously Talon Therapeutics) and Pfizer to lead the acute lymphocytic/lymphoblastic leukemia therapeutics pipeline with continuous innovations and new product launches in the forecast period (2013 to 2020)

In this market, Linker regimen and Hyper-CVAD regimen are the leading therapies, accounting for a share of approximately 65% - 70% of the overall market in 2013. Marqibo is the only drug in pipeline, which is currently commercially available in the market for treatment of acute lymphocytic/lymphoblastic leukemia in adults. A notable development in this market is that the market expiration of Arranon and Clolar (currently available drugs) will result in slight market erosion for these drugs. However, the overall market growth will be backed by the launch of new drugs (Graspa, Marqibo, and Inotuzumab Ozogamicin) in the market, which are currently under different stages of Phase III clinical trials.

The overall acute lymphocytic/lymphoblastic leukemia therapeutics market space is marked by increasing investment by market players towards development of innovative products. These investments are focused towards addressing the existing unmet needs in the market. Acquisition has been identified as one of the most prominent market entry strategies from most market players to enter the acute lymphocytic/lymphoblastic leukemia therapeutics market. Other than this, partnerships, collaborations, and joint ventures with research organizations are also widely accepted growth strategies by companies, to develop new products in the market.

Related Reports:

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market (Pipeline Forecast & Market Forecast in G8 Countries) (2011 2020).
https://www.marketsandmarkets.com/Market-Reports/acute-lymphocytic-leukemia-therapeutics-market-518.html

Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com

Report Code
PH 1729
Published ON
Dec, 2013
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved